CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
病例报告：源自脐血移植受者的 CD19 CAR-T 细胞有效治疗 UCBT 后复发的急性淋巴细胞白血病
英文原题：Case Report: CD19 CAR-T cells derived from recipient of umbilical cord blood transplantation effectively treated relapsed acute lymphoblastic leukemia after UCBT.
查看英文原题
Case Report: CD19 CAR-T cells derived from recipient of umbilical cord blood transplantation effectively treated relapsed acute lymphoblastic leukemia after UCBT.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）近期进展为异基因造血干细胞移植（allo-HSCT）后复发的急性淋巴细胞白血病患者提供了另一种治疗方法。然而，异基因脐带血移植（UCBT）后复发患者因缺少脐带血，无法获得供者来源CAR-T 细胞。我们报告一例Ph⁺急性淋巴细胞白血病患者在UCBT后复发，接受UCBT后受者自身来源的CD19 CAR-T 细胞治疗后达到形态学和分子学完全缓解。患者仅出现1级细胞因子释放综合征（CRS），未观察到GVHD或神经毒性。CAR-T 细胞输注后超过6年，患者仍维持血液学和分子学完全缓解，微小残留病（MRD）检测阴性。本病例首次展示了一种新策略：使用UCBT受者自身来源的CD19 CAR-T 细胞治疗UCBT后复发的急性淋巴细胞白血病，具有可行性、疗效和安全性。
展开英文摘要原文
Recent advances in chimeric antigen receptors have provided an alternative approach for treating relapsed acute lymphocyte leukemia after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
However, relapsed patients who had undergone allogeneic umbilical cord blood transplantation (UCBT) have no chance of having CAR-T cells derived from donors due to lacking UCB.
We present a case of a patient with Ph+ ALL who relapsed after UCBT and achieved complete morphological and molecular remission following treatment with CD19 CAR-T cells derived from the recipient post-UCBT. The patient had only grade I CRS. GVHD or neurotoxicity was not observed.
More than 6 years after CAR-T cell infusion, the patient was still in hematologic and molecular complete remission with negative minimal residual disease (MRD). This case is the first to show a new strategy of practicality, efficacy, and safety of CD19 CAR-T cells derived from UCBT recipients for treating relapsed ALL after UCBT.
论文信息
- 作者
- Li H、Li X、Xian N、Huang G、Li N
- 第一作者单位
- Department of Hematology, Xiamen Medical College Affiliated Second Hospital, Xiamen, China.China
- 通讯作者单位
- Hematopoietic Stem Cell Transplantation Center, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Department of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.China
- 文献类型
- 病例报告
- 期刊
- Frontiers in immunology2025
- 原文标识
- PubMed 40458395 · DOI 10.3389/fimmu.2025.1586349
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →